- Nachrichtendetail
-
26.04.2024 11:55:36 - dpa-AFX: EQS-News: CHEPLAPHARM closes financial year 2023 with record revenue and double-digit growth (english)
CHEPLAPHARM closes financial year 2023 with record revenue and double-digit
growth
EQS-News: Cheplapharm AG / Key word(s): Annual Results/Annual Report
CHEPLAPHARM closes financial year 2023 with record revenue and double-digit
growth
26.04.2024 / 11:55 CET/CEST
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
CHEPLAPHARM CLOSES FINANCIAL YEAR 2023 WITH RECORD REVENUE AND DOUBLE-DIGIT
GROWTH
Greifswald, 26th April 2024
* EBITDA increases significantly by +14% YoY to EUR 780.5 million (FY2022: EUR 685.7 million)
* Number of employees grows to 666, an increase of 24% (FY2022: 535)
The CHEPLAPHARM Group, a global leader in the acquisition of originator
products from the research-based pharmaceutical industry, closed the
financial year 2023 with a record revenue of EUR 1,498.4 million. The company,
headquartered in Greifswald/Germany, is continuing its dynamic and
profitable double-digit percentage growth track. In addition to the revenue
record, the opening of the affiliates in Japan and Switzerland are important
milestones in the transformation to an international group of companies. The
largest transaction in the company's history, the acquisition of the Zyprexa®
portfolio from Eli Lilly for a purchase price of around EUR 1.3 billion,
rounds off the successful financial year 2023.
The annual financial statements for the financial year 2023 published today
show a year-over-year increase in revenue of +17% to EUR 1,498.4 million
(FY2022: EUR 1,279.5 million). EBITDA totalled EUR 780.5 million in the
reporting period, an increase of +14% compared to the financial year 2022
(FY2020: EUR 685.7 million). At 52%, the EBITDA margin remained at a high and
industry-leading level in 2023. CHEPLAPHARM is thus continuing its dynamic
and profitable growth track over the last years in 2023 as well and
significantly exceeding the targets it has set itself.
The strong growth in revenue and earnings was driven by the successful
acquisitions in 2023, with the largest transaction in the company's history
making a particularly significant contribution to growth. In July 2023,
CHEPLAPHARM acquired the Zyprexa® portfolio from Eli Lilly for around EUR 1.3
billion. Further acquisitions of products from Roche (Xeloda® - China and
Japan), AstraZeneca (Pulmicort Flexhaler® - USA) and Teva (Myocet® - Europe)
also had a positive impact on revenue development and the further
diversification of the portfolio. In total, CHEPLAPHARM invested around EUR
1.8 billion in acquisitions of established branded products in 2023, a
record level of investment.
"We look back on an extremely successful year 2023 and continued to grow
profitably in a challenging market environment. In addition to this dynamic
growth, we have also consistently driven forward our transformation into an
international group of companies. Within just a few months, we have
established two fully operational affiliates in Japan and Switzerland with
over 30 new colleagues," says Edeltraud Lafer, CEO of CHEPLAPHARM,
summarising the positive results.
With the two subsidiaries in two globally important pharmaceutical markets,
CHEPLAPHARM is expanding and strengthening its global presence. The new
locations will enable economies of scale to be realised and profitability to
be further increased.
"In the financial year 2023, we were also very successful on the capital
market and raised more than one billion euros with two bonds," adds Dr Kia
Parssanedjad, CFO of CHEPLAPHARM. "This enabled us to finance the
acquisition of the Zyprexa® portfolio and further strengthen our liquidity
position. The two successful placements demonstrate investors' great
confidence in the strength and resilience of our business model and give us
the flexibility to further invest in attractive branded medicines in the
current financial year 2024 and thus continue our growth track."
As a profitable and steadily growing company, CHEPLAPHARM is an attractive
employer. The number of employees rose by 131 to 666 at the end of the year,
an increase of 24% compared to the previous year. The majority of the new
colleagues started work at the headquarters in Greifswald. This means that
CHEPLAPHARM remains one of the most important employers in the region.
About CHEPLAPHARM
CHEPLAPHARM is a family-owned company with headquarters in Greifswald. For
over 20 years, the company has been very successful in taking over
well-known and well-established medicines from the research-based
pharmaceutical industry and transferring them to an existing global network
of partners for production and distribution. In this way, CHEPLAPHARM
ensures the continuous supply of these medicines to patients worldwide. In
addition to its headquarters in Greifswald, CHEPLAPHARM operates further
sites in France, Japan, Russia and Switzerland. The company employs around
700 people worldwide.
Please refer to www.cheplapharm.com for additional information.
Press office:
CHEPLAPHARM Ziegelhof 24 17489 Greifswald press(at)cheplapharm.com
---------------------------------------------------------------------------
26.04.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS
News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The EQS Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com
---------------------------------------------------------------------------
Notierung vorgesehen
End of News EQS News Service
---------------------------------------------------------------------------
1890701 26.04.2024 CET/CEST
growth
EQS-News: Cheplapharm AG / Key word(s): Annual Results/Annual Report
CHEPLAPHARM closes financial year 2023 with record revenue and double-digit
growth
26.04.2024 / 11:55 CET/CEST
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
CHEPLAPHARM CLOSES FINANCIAL YEAR 2023 WITH RECORD REVENUE AND DOUBLE-DIGIT
GROWTH
Greifswald, 26th April 2024
* Double-digit revenue growth again: +17% YoY to EUR 1,498.4 million
(FY2022: EUR 1,279.5 million)
* EBITDA increases significantly by +14% YoY to EUR 780.5 million (FY2022: EUR 685.7 million)
* EBITDA margin remains at a high and industry-leading level of 52%
(FY2022: 54%)
* New affiliates in Japan and Switzerland drive transformation into an
international group of companies
* Number of employees grows to 666, an increase of 24% (FY2022: 535)
The CHEPLAPHARM Group, a global leader in the acquisition of originator
products from the research-based pharmaceutical industry, closed the
financial year 2023 with a record revenue of EUR 1,498.4 million. The company,
headquartered in Greifswald/Germany, is continuing its dynamic and
profitable double-digit percentage growth track. In addition to the revenue
record, the opening of the affiliates in Japan and Switzerland are important
milestones in the transformation to an international group of companies. The
largest transaction in the company's history, the acquisition of the Zyprexa®
portfolio from Eli Lilly for a purchase price of around EUR 1.3 billion,
rounds off the successful financial year 2023.
The annual financial statements for the financial year 2023 published today
show a year-over-year increase in revenue of +17% to EUR 1,498.4 million
(FY2022: EUR 1,279.5 million). EBITDA totalled EUR 780.5 million in the
reporting period, an increase of +14% compared to the financial year 2022
(FY2020: EUR 685.7 million). At 52%, the EBITDA margin remained at a high and
industry-leading level in 2023. CHEPLAPHARM is thus continuing its dynamic
and profitable growth track over the last years in 2023 as well and
significantly exceeding the targets it has set itself.
The strong growth in revenue and earnings was driven by the successful
acquisitions in 2023, with the largest transaction in the company's history
making a particularly significant contribution to growth. In July 2023,
CHEPLAPHARM acquired the Zyprexa® portfolio from Eli Lilly for around EUR 1.3
billion. Further acquisitions of products from Roche (Xeloda® - China and
Japan), AstraZeneca (Pulmicort Flexhaler® - USA) and Teva (Myocet® - Europe)
also had a positive impact on revenue development and the further
diversification of the portfolio. In total, CHEPLAPHARM invested around EUR
1.8 billion in acquisitions of established branded products in 2023, a
record level of investment.
"We look back on an extremely successful year 2023 and continued to grow
profitably in a challenging market environment. In addition to this dynamic
growth, we have also consistently driven forward our transformation into an
international group of companies. Within just a few months, we have
established two fully operational affiliates in Japan and Switzerland with
over 30 new colleagues," says Edeltraud Lafer, CEO of CHEPLAPHARM,
summarising the positive results.
With the two subsidiaries in two globally important pharmaceutical markets,
CHEPLAPHARM is expanding and strengthening its global presence. The new
locations will enable economies of scale to be realised and profitability to
be further increased.
"In the financial year 2023, we were also very successful on the capital
market and raised more than one billion euros with two bonds," adds Dr Kia
Parssanedjad, CFO of CHEPLAPHARM. "This enabled us to finance the
acquisition of the Zyprexa® portfolio and further strengthen our liquidity
position. The two successful placements demonstrate investors' great
confidence in the strength and resilience of our business model and give us
the flexibility to further invest in attractive branded medicines in the
current financial year 2024 and thus continue our growth track."
As a profitable and steadily growing company, CHEPLAPHARM is an attractive
employer. The number of employees rose by 131 to 666 at the end of the year,
an increase of 24% compared to the previous year. The majority of the new
colleagues started work at the headquarters in Greifswald. This means that
CHEPLAPHARM remains one of the most important employers in the region.
About CHEPLAPHARM
CHEPLAPHARM is a family-owned company with headquarters in Greifswald. For
over 20 years, the company has been very successful in taking over
well-known and well-established medicines from the research-based
pharmaceutical industry and transferring them to an existing global network
of partners for production and distribution. In this way, CHEPLAPHARM
ensures the continuous supply of these medicines to patients worldwide. In
addition to its headquarters in Greifswald, CHEPLAPHARM operates further
sites in France, Japan, Russia and Switzerland. The company employs around
700 people worldwide.
Please refer to www.cheplapharm.com for additional information.
Press office:
CHEPLAPHARM Ziegelhof 24 17489 Greifswald press(at)cheplapharm.com
---------------------------------------------------------------------------
26.04.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS
News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The EQS Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com
---------------------------------------------------------------------------
Language: English
Company: Cheplapharm AG
Ziegelhof 24
17489 Greifswald
Germany
Phone: 03834 3914 O
E-mail: info@cheplapharm.com
Internet: www.cheplapharm.com
ISIN: DE000CHP2222
WKN: CHP222
EQS News ID: 1890701
Notierung vorgesehen
End of News EQS News Service
---------------------------------------------------------------------------
1890701 26.04.2024 CET/CEST
